Drug Profile
VTP 400
Alternative Names: ChAdOx1-VZV; CSB-016; VTP-400Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator University of Oxford
- Developer Barinthus Biotherapeutics; Tianjin CanSino Biotechnology
- Class DNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Herpes zoster
Most Recent Events
- 07 Nov 2023 Phase-I clinical trials in Herpes zoster (Prevention) in Canada (IM) (NCT05991427)
- 07 Nov 2023 Phase-I clinical trials in Herpes zoster (Prevention) in Canada (Inhalation) (NCT05991427)
- 06 Aug 2023 CanSino Biologics plans a phase I trial in Herpes zoster (prevention) in Canada (IM and Inhalation) in September 2023 (NCT05991427)